The effects of omega-3 fatty acids supplementation on type 2 diabetes mellitus

The assesment of the effects of omega 3 faty acid supplementation on serum level of Omentin , Chemerin and TNF-alpha in patients with type 2 diabetes mellitus

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017092724081N3

Enrollment

Registered

2017-11-01

Start date

2012-01-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: Intervention group: four softgels of ?-3 per day, containing 310 mg EPA, 210 mg DHA, 110 mg other polyunsaturated fatty acids and five mg vitamin E. Intervention 2: Control group: four

Treatment - Drugs

Intervention group: four softgels of ?-3 per day, containing 310 mg EPA, 210 mg DHA, 110 mg other polyunsaturated fatty acids and five mg vitamin E

Control group: four placebo softgels a day, containing paraffin oil with the same size and color as ?-3 fatty acid soft gels

Eligibility

Sex/Gender

All

Age

40 Years to 65 Years

Inclusion criteria

Inclusion criteria: The criteria for inclusion were as follows: 30-65 years of age; T2DM diagnosis; and BMI in the range of 18.5 to 40 kg/m2. Patients with a history of diseases including chronic renal; hepatic; gastrointestinal; hematological diseases; and thyroid disorder as well as pregnant and lactating patients were excluded from the study. Furthermore, Patients who were treated with insulin; Thiazolidinediones or consumed weight loss drugs and any nutritional supplement 2 weeks prior to the beginning of the study were excluded from the study. The exclusion criteria: Unwillingness to cooperate; change the dose or type of anti-diabetes drug; incidence of any sensitivity Interventions.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Omentin. Timepoint: Pre-intervention/10 weeks after intervention. Method of measurement: ELISA - mg/dl.;Chemerin. Timepoint: Pre-intervention/10 weeks after intervention. Method of measurement: ELISA - mg/dl.;TNF-alpha. Timepoint: Pre-intervention/10 weeks after intervention. Method of measurement: ELISA - pg/dl.	—

Secondary

Measure	Time frame
Insulin. Timepoint: Pre-intervention/10 weeks after intervention. Method of measurement: ELISA/µIU/ml.;HOMA-IR. Timepoint: Pre-intervention/10 weeks after intervention. Method of measurement: fasting insulin (µIU/ml) × fasting glucose (mmol/ml)/22.5.;QUICKI. Timepoint: Pre-intervention/10 weeks after intervention. Method of measurement: 1/{log[fasting insulin (µU/mL)] + log[fasting glucose (mg/dL)].	—

Measure

Time frame

Insulin. Timepoint: Pre-intervention/10 weeks after intervention. Method of measurement: ELISA/µIU/ml.;HOMA-IR. Timepoint: Pre-intervention/10 weeks after intervention. Method of measurement: fasting insulin (µIU/ml) × fasting glucose (mmol/ml)/22.5.;QUICKI. Timepoint: Pre-intervention/10 weeks after intervention. Method of measurement: 1/{log[fasting insulin (µU/mL)] + log[fasting glucose (mg/dL)].

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNiaz Mohammadzade Honarva

Tehran University of Medical Sciences

honarvar@tums.ac.ir+98 21 8897 4461

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026